ArticleScientific reports2025
Lycium barbarum glycopeptide mitigates retinal ischemia-reperfusion injury through its anti-inflammatory, anti- senescence, and anti-apoptosis properties.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Mechanisms ofFood science & nutrition · 2026Article
- Diet and Medicinal Herbs as Adjunctive Approaches to Immune Homeostasis in Sjögren's Disease.International journal of molecular sciences · 2026Review
- Article
- Research progress on active ingredients of traditional Chinese medicine in the treatment of asthenozoospermia.Frontiers in reproductive health · 2026Review
- Lycium barbarum glycopeptide confers neuroprotection in chronic ocular hypertensive rats: a study investigating visual function, retinal structure, microcirculation, and pyroptosis.Frontiers in pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
This study investigates the therapeutic potential of lycium barbarum glycopeptide (LbGp) in mitigating retinal ischemia-reperfusion injury (RIRI), a key pathological mechanism in glaucoma. RIRI involves inflammation, cellular senescence, and apoptosis, leading to retinal ganglion cell (RGC) degeneration and optic nerve damage. Using in vivo and in vitro models, the study evaluated LbGp's anti-inflammatory, anti-senescence, and anti-apoptotic properties. In vivo, RIRI was induced in C57BL/6J mice by elevating intraocular pressure, followed by reperfusion, with LbGp administered orally. In vitro, R28 cells underwent oxygen-glucose deprivation/reoxygenation (OGD/R) to simulate RIRI, with LbGp added to cultures. Retinal structure and function were assessed using optical coherence tomography (OCT), OCT angiography (OCTA), and hematoxylin-eosin (HE) staining, while inflammatory markers (IL-6, IL-1β, TNFα), senescence markers (p21, p16), and apoptosis were evaluated via immunofluorescence, enzyme linked immunosorbent assay (ELISA), senescence-associated β-galactosidase (SA-β-gal) staining, terminal dUTP Nick End Labeling (TUNEL) assays, and flow cytometry (FCM). Results showed LbGp restored retinal blood flow, reduced retinal thinning, and improved RGC survival, while decreasing inflammatory, senescence and apoptosis markers. These findings suggest LbGp is a promising therapeutic candidate for glaucoma and ischemic retinal conditions, warranting further research to elucidate its mechanisms and clinical efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.